The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
Hana Financial Group
086790.KS · KRX · KRW · Market cap $32.46T
Hana Financial Group Inc., through its subsidiaries, provides financial services in South Korea, Hong Kong, Singapore, the United States, Japan, China, Indonesia, the United Kingdom, Canada, and internationally.
Not yet scoredAt the last full screen
2026-06-14
Screened 2026-06-14 · the tape above runs as of 22:40 UTC · 24 Jul · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markup label.
Hana Financial Group holds its Markup at $121,000.00. Consolidating, no directional conviction, held for 3 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 3 days |
| Price at the screen | $121,000.00 |
| Valuation | N/A trailing · 6.89 forward price to earnings |
| Values screen | Not scored · score 30.0 |
| Beta | 0.73 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Bank — FAIL on business activity | Fail |
| Debt load | 17.13% | Below 33% | Interest-bearing debt is just 17.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 6.42% | Below 33% | Cash held in interest-bearing accounts and securities is 6.4% of assets, under the one-third limit. | Pass |
| Receivables | 2.67% | Below 49% | Money owed to the company is 2.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 63.68% | Below 5% | 63.7% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 24% discount to our $150,000.00 fair value, 25.70% revenue growth.
Fair value range in KRW, drawn from the 2026-06-14 screen. The gold marker is the market price at the same screen. A 24.0% margin of safety to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +24% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-06-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 6.9x forward earnings, the price already runs ahead of the business. Our fair value sits at $150,000.00, below where it trades today.
| Forward P/E | 6.9xcheap for a company growing this fast |
| Revenue growth | +25.7%strong top-line growth |
| Profit margin | 29.1%healthy profit margins |
| Return on equity | 9.1%a modest return on shareholder capital |
| Dividend yield | 379.00% |
| Beta | 0.73steadier than the market |
| 52-week range | 77,100.00 - 133,700.00 |
| Market cap | $32.46T |
The risks · The things to watch: its business and earnings are exposed to South Korea and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade086790.KS trades on KRX (the company is based in South Korea). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it strong buy, with a mean price target of $150286. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $126,600.00 | -6.9% | · | $931 | -6.9% |
| 2 months | $118,437.68 | -0.5% | $1,145.00 | $1,005 | +0.5% |
| 3 months | $111,499.91 | +5.7% | $1,145.00 | $1,068 | +6.8% |
| 6 months | $90,879.88 | +29.7% | $2,511.00 | $1,325 | +32.5% |
| 1 year | $75,219.48 | +56.7% | $4,344.00 | $1,625 | +62.5% |
| 2 years | $53,838.30 | +119.0% | $8,250.00 | $2,343 | +134.3% |
| 3 years | $35,543.71 | +231.7% | $11,650.00 | $3,645 | +264.5% |
| 5 years | $32,786.71 | +259.6% | $18,700.00 | $4,166 | +316.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever 086790.KS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.